Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)—an intermediate endocytic compartment—with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB—a type of intraluminal vesicles (ILV’s)—buds inward into the endosomal lumen.
DelveInsight’s,“Exosomes Pipeline Insight, 2021” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for free sample page: https://www.delveinsight.com/sample-request/exosomes-pipeline-insight
Some of Exosomes Companies:
- Direct Biologics
- Codiak BioSciences
- ExoCyte Therapeutics
- Avalon GloboCare
- United Therapeutics Corporation
- Capricor Therapeutics
- Avalon GloboCare
- Azymus Therapeutics
- Versatope Therapeutics
- Lamellar Biomedical
- Celltrion
- And Many Others
Request for free sample page: https://www.delveinsight.com/sample-request/exosomes-pipeline-insight
DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of Exosomes Therapies:
- LAMELLASOME IPF-NA
- exoSTING
- ET-08
- AVA 201
- Unexisome
- CAP 2003
- exoIL 12
- AVA 203
- AZ 001
- VT 105
- And Many Others
Request for free sample page: https://www.delveinsight.com/sample-request/exosomes-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Exosomes: Overview
Formation
Exosomes in CNS Disease
Exosomes in Oncology
Exosomes in Other Diseases
• Advantages and disadvantages
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Exosomes – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Exosomes companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Exosomes Collaboration Deals
Mid Stage Products (Phase I/II)
• Comparative Analysis
MPCs-derived exosomes: Cellular Biomedicine Group Ltd.
Pre-clinical and Discovery Stage Products
• Comparative Analysis
exoSTING: Codiak BioSciences
AVA 201: Avalon GloboCare
UNEX 42: United Therapeutics Corporation
CAP 2003: Capricor Therapeutics
AB 126: ArunA Biomedical
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Exosomes Key Companies
Exosomes Key Products
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Exosomes- Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix
Request for Deatiled TOC: https://www.delveinsight.com/sample-request/exosomes-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight